

BIOPHARMACEUTICAL INNOVATORS ARE LEADING THE CHARGE IN FIGHT AGAINST CORONAVIRUS

As the threat of the novel coronavirus continues to grow globally, innovative biopharmaceutical companies are ramping up efforts to study the virus and develop vaccines and antivirals.

BIO member companies are working closely with U.S. government agencies, Chinese authorities, non-governmental entities and the World Health Organization to identify their most pressing needs in the areas of vaccination, diagnostics, antivirals, and other treatments, and to facilitate collaborations with industry.

Here's a snapshot of how our industry – comprised of both large and small innovators – is responding:



A biotech innovator – in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), and the Coalition for Epidemic Preparedness Innovations (CEPI) – **has developed a vaccine using mRNA technology** with hopes to begin human tests of their product in April.



An innovative drug developer, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), **will soon launch two Phase III clinical trials of its investigational antiviral.**



A leading biopharmaceutical company is working with Health and Human Services' Biomedical Advanced Research and Development Authority, better known as BARDA, **to develop a vaccine using a platform it currently uses to make a licensed influenza vaccine.**



A cutting-edge biotech company – with support from CEPI – is **developing a new coronavirus vaccine.** CEPI is also working with other industry leaders **to accelerate the development of vaccines.**



At least a dozen companies have **begun or accelerated development of vaccines and antiviral therapies.**




Work previously done on medical countermeasures (MCMs) against other coronaviruses including SARS and MERS are **being tested against COVID-19.**



Numerous antiviral drugs and biologics are being investigated and several **have entered clinical trials to test for efficacy and safety against COVID-19.**

Biotech Companies Are Responding Faster Than Ever to Emerging Health Threats

VACCINE DEVELOPMENT: Months from viral genetic-sequence data publication to first human study



Source: National Institute of Allergy and Infectious Diseases